Alivus Life Sciences DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY24Mar 2024FY23Mar 2023FY22Mar 2022
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.75×0.75×0.74×0.74×
1.06×1.02×1.05×0.98×
31.3%27.2%27.8%27.2%
0.82×0.82×0.84×0.86×
1.20×1.22×1.26×1.20×
24.5%20.7%22.9%20.4%
21.1%21.1%22.3%20.4%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALIVUS₹1,397.40

Alivus Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAARTIDRUGSAKUMSAGARWALEYEAPLLTDADVENZYMESAARTIPHARMCORONA
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
Last 12M
30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.740.740.750.75
Interest Burden (Pretax/EBIT) ×0.981.051.021.06
EBIT Margin %27.2327.7727.1931.31
Asset Turnover ×0.860.840.820.82
Financial Leverage (Assets/Equity) ×1.201.261.221.20
ROE (5-step product, year-end total equity) %20.4022.9420.6724.46
ROE (owners' profit / average owners' equity) %20.3822.2821.0721.07
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.